[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552780":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":37,"responsibleParty":73,"collaborators":31,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":31,"eligibilityCriteria":81,"healthyVolunteers":77,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":31,"studyType":88,"phases":89,"briefSummary":92,"conditions":93,"keywords":31,"overallStatus":39,"whyStopped":31,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Shanghai Huaota Biopharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HB0034","EXPERIMENTAL","single-arm and all the patients would receive HB0034 300mg i.v. every other four weeks",[13],"Drug: HB0034",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","300mg, i.v. Q4W",[9],[20],"Anti-IL-36R antibody,Recombinant Humanized anti-IL-36R Monoclonal antibody",[22],{"name":23,"affiliation":24,"role":25},"Jianzhong Zhang, PhD","Peking University People's Hospital (PKUPH)","PRINCIPAL_INVESTIGATOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Guodong Zhou","CONTACT","+86 13636638684",null,"guodong.zhou@huaota.com",{"name":34,"role":29,"phone":35,"phoneExt":31,"email":36},"Qiaoxia Qian, Master","+86 18555690860","qiaoxia.qian@huaota.com",[38,56,61],{"facility":24,"status":39,"city":40,"state":31,"zip":31,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Beijing","China","CN",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50,54],{"name":51,"role":29,"phone":52,"phoneExt":31,"email":53},"Jianzhong zhang","+8618555690860","qiaoxia.qian@huata.com",{"name":55,"role":25,"phone":31,"phoneExt":31,"email":31},"Jianzhong zhang, PhD",{"facility":57,"status":39,"city":40,"state":31,"zip":31,"country":41,"countryCode":42,"cosmosGeoPoint":58,"geoPoint":60,"contacts":31},"Peking University People's Hospital",{"type":44,"coordinates":59},[46,47],{"lat":47,"lon":46},{"facility":62,"status":39,"city":63,"state":31,"zip":31,"country":41,"countryCode":42,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"The Second affiliated Hospital zhejiang University School of Medicine","Hangzhou",{"type":44,"coordinates":65},[66,67],120.16142,30.29365,{"lat":67,"lon":66},[70],{"name":71,"role":29,"phone":35,"phoneExt":31,"email":72},"Xiaoyong Man, Phd","xiaoyong.man@gmail.com",{"type":74,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100552780","phase-2-long-term-safety-and-efficacy-of-hb0034-in-subjects-with-generalized-pustular-psoriasis-100552780",false,"NCT06477536","Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis","A Phase IIb, Long-Term Extension Study to Evaluate the Safety and Efficacy of HB0034 in the Treatment of Adult Subjects With Generalized Pustular Psoriasis","Inclusion Criteria:\n\n* Patients participated in the preceding placebo-controlled Phase 2 study （HB0034-04）and completed at least the Week 12 visit of the HB0034-04 study\n* Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment\n* Men and women of reproductive age who have no parenting plans and are willing to use reliable contraception during the study period and for 6 months after the last dose of the study drug;\n* Patients who fully understand and voluntarily sign an ICF, and are willing and able to follow clinical study and subsequent visit schedules\n\nExclusion Criteria:\n\n* Patients who are experiencing GPP flare","ALL","18 Years","75 Years",{"count":86,"type":87},33,"ESTIMATED","INTERVENTIONAL",[90,91],"PHASE2","PHASE3","This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).",[94],"Generalized Pustular Psoriasis","2025-02-12",{"date":97,"type":98},"2025-02-14","ACTUAL",{"date":100,"type":98},"2024-09-02",{"date":102,"type":87},"2026-06-30",{"name":5,"class":6},3]